.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Merck
QuintilesIMS
Accenture
Dow
Harvard Business School
Julphar
Federal Trade Commission
Cantor Fitzgerald
Baxter

Generated: December 16, 2017

DrugPatentWatch Database Preview

EFFIENT Drug Profile

« Back to Dashboard

Which patents cover Effient, and what generic alternatives are available?

Effient is a drug marketed by Eli Lilly And Co and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has seventy patent family members in thirty-one countries and eight supplementary protection certificates in seven countries.

The generic ingredient in EFFIENT is prasugrel hydrochloride. There are nineteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the prasugrel hydrochloride profile page.
Drug patent expirations by year for EFFIENT

Pharmacology for EFFIENT

Medical Subject Heading (MeSH) Categories for EFFIENT

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly And CoEFFIENTprasugrel hydrochlorideTABLET;ORAL022307-001Jul 10, 2009ABRXYesNo► Subscribe► SubscribeY► Subscribe
Eli Lilly And CoEFFIENTprasugrel hydrochlorideTABLET;ORAL022307-002Jul 10, 2009ABRXYesYes► Subscribe► SubscribeY► Subscribe
Eli Lilly And CoEFFIENTprasugrel hydrochlorideTABLET;ORAL022307-001Jul 10, 2009ABRXYesNo► Subscribe► Subscribe► Subscribe
Eli Lilly And CoEFFIENTprasugrel hydrochlorideTABLET;ORAL022307-002Jul 10, 2009ABRXYesYes► Subscribe► SubscribeY► Subscribe
Eli Lilly And CoEFFIENTprasugrel hydrochlorideTABLET;ORAL022307-001Jul 10, 2009ABRXYesNo► Subscribe► SubscribeY► Subscribe
Eli Lilly And CoEFFIENTprasugrel hydrochlorideTABLET;ORAL022307-001Jul 10, 2009ABRXYesNo► Subscribe► SubscribeY► Subscribe
Eli Lilly And CoEFFIENTprasugrel hydrochlorideTABLET;ORAL022307-002Jul 10, 2009ABRXYesYes► Subscribe► SubscribeY► Subscribe
Eli Lilly And CoEFFIENTprasugrel hydrochlorideTABLET;ORAL022307-001Jul 10, 2009ABRXYesNo► Subscribe► Subscribe► Subscribe
Eli Lilly And CoEFFIENTprasugrel hydrochlorideTABLET;ORAL022307-002Jul 10, 2009ABRXYesYes► Subscribe► Subscribe► Subscribe
Eli Lilly And CoEFFIENTprasugrel hydrochlorideTABLET;ORAL022307-002Jul 10, 2009ABRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for EFFIENT

Drugname Dosage Strength RLD Submissiondate
prasugrel hydrochlorideTablets5 mg and 10 mgEffient7/10/2013

Non-Orange Book Patents for Tradename: EFFIENT

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,436,242 Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof for inhibiting blood platelet aggregation► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: EFFIENT

Country Document Number Estimated Expiration
Denmark0542411► Subscribe
Germany122009000045► Subscribe
Poland206138► Subscribe
Norway923484► Subscribe
European Patent Office0542411► Subscribe
Germany69226607► Subscribe
World Intellectual Property Organization (WIPO)02051412► Subscribe
Austria407675► Subscribe
Hungary218785► Subscribe
MexicoPA03005770► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: EFFIENT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00397Netherlands► SubscribePRODUCT NAME: PRASUGREL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/08/503/001-014 20090225
0542411/01Switzerland► SubscribeFORMER REPRESENTATIVE: BOHEST AG, CH
C/GB09/032United Kingdom► SubscribePRODUCT NAME: PRASUGREL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/08/503/001 20090225; UK EU/1/08/503/002 20090225; UK EU/1/08/503/003 20090225; UK EU/1/08/503/004 20090225
C0031France► SubscribePRODUCT NAME: PRASUGREL; NAT. REGISTRATION NO/DATE: EU/1/08/503/001-014 20090225; FIRST REGISTRATION: EU/1/08/503/001/-014 20090225
589Luxembourg► Subscribe91589, EXPIRES: 20170909
0397Netherlands► Subscribe300397, 20120909, EXPIRES: 20170908
2009 00024Denmark► Subscribe
C021/2009Ireland► SubscribeSPC021/2009: 20091119, EXPIRES: 20170908
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Johnson and Johnson
Cantor Fitzgerald
Dow
AstraZeneca
Moodys
Chinese Patent Office
Colorcon
Covington
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot